Effectiveness and safety of eribulin for human epidermal growth factor receptor 2 negative metastatic breast cancer in a real-world population

• Published in: Journal of oncology pharmacy practice Vol. 28; no. 7; pp. 1573 - 1582
• Main Authors: Díaz-Acedo, Rocío, Artacho Criado, Silvia, Jiménez Galán, Rocío, Gutiérrez Pizarraya, Antonio, Galván Banqueri, Mercedes, Rodríguez-de-la-Borbolla-Artacho, María, Marcos Rodríguez, José Antonio, Márquez Saavedra, Esther
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01-10-2022; Sage Publications Ltd
• Subjects: Breast cancer; Clinical trials; Confidence intervals; Epidermal growth factor; Metastases; Metastasis; Patients; Safety; Survival; capecitabine; Eribulin; human epidermal growth factor receptor-2 negative; metastatic breast cancer
• ISSN: 1078-1552; 1477-092X
• DOI: 10.1177/10781552211038241

Background
Eribulin’s clinical benefit remains unclear; so, studies analyzing its effectiveness in routine clinical practice are interesting.
Patients and methods
This is a multicenter, retrospective study including patients with human epidermal growth factor receptor-2-negative metastatic breast cancer which assesses effectiveness and safety of eribulin.
Results
A total of 140 women were included, with a median age of 57 years. The median overall survival and progression-free survival were 8.8 (95% confidence interval: 6.1–11.4) and 2.8 months (95% confidence interval: 2.5–3.1), respectively. For patients with hormonal receptor expression, a significantly longer progression-free survival was observed: 3.4 (95%confidence interval: 2.3–4.5) versus triple negative: 2.0 (95%confidence interval: 1.7–2.3) months, p = 0.003. Also, those who had received capecitabine prior to eribulin had a higher median overall survival than those who had not received it (9.5 months, 95% confidence interval: 6.6–12.5 vs. 4.8 months, 95% confidence interval: 3.4–6.2; p = 0.001). When only triple-negative patients were included, median overall survival was 6.5 (95% confidence interval: 0.1–16.2) for those who had received previous capecitabine versus 4.3 (95% confidence interval: 2.8–5.8) months for patients who had not received it; p =0.006. The safety profile of eribulin was adequate.
Conclusion
Effectiveness of eribulin in a real-life human epidermal growth factor receptor-2--negative population is lower than that observed in clinical trials. Its benefit seems to be higher in patients with hormonal receptor expression and patients who had received capecitabine prior to eribulin. The safety profile of eribulin is adequate.